1616340-94-3

Usage

Uses

Used in Pharmaceutical Industry:
(2R,5S,13aR)-8-methoxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide is used as a pharmaceutical compound for its potential therapeutic effects on certain diseases or conditions. Its unique structure and functional groups may contribute to its efficacy in targeting specific biological pathways or receptors, making it a promising candidate for drug development and treatment strategies.

Upstream product

• 214759-21-4 (2,4,6-trifluorophenyl)methanamine 
• 1616342-45-0 (2R,5S,13aR)-8-methoxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxylic acid 
• 3282-30-2 pivaloyl chloride 
• 124555-33-5 (1R,3S)-3-aminocyclopentan-1-ol hydrochloride 
• 1335210-23-5 1-[2,2-bis(methyloxy)ethyl]-5-(methyloxy)-6-[(methyloxy)carbonyl]-4-oxo-1,4-dihydro-3-pyridinecarboxylic acid 
• 1616340-75-0 1-(2,2-dihydroxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid 

Downstream Products

• 1611493-60-7 GS-9883 

Relevant academic research and scientific papers

Process for Preparation of Intermediates Used for the Synthesis of HIV Integrase Inhibitor

Provided herein is a process for the intermediates used for preparation of HIV Integrase Inhibitor such as Bictegravir, Dolutegravir, Cabotegravir or their pharmaceutically acceptable salts.

PROCESS AND POLYMORPHIC FORMS OF BICTEGRAVIR AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS OR CO-CRYSTALS THEREOF

The present invention generally relates to polymorphic forms of bictegravir, its salts, co-crystals, solvates or hydrates thereof and process for the preparation of the same and also relates to pharmaceutical compositions containing the same. The present

CONTINUES FLOW PROCESS FOR THE PREPARATION OF ACTIVE PHARMACEUTICAL INGREDIENTS - POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES AND INTERMEDIATES THEREOF

The present invention discloses continues flow process for the preparation of polycyclic carbamoyl pyridone derivatives and intermediates thereof. In particular, the present invention discloses a process for the preparation of intermediate. Formule (V).

POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE

Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Ζ1 and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.